Core Insights - Cardinal Health, Inc. reported first-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.55, exceeding the Zacks Consensus Estimate of $2.21 by 15.4%, and showing a year-over-year improvement of 35.6% [1][8] - Total revenue for the quarter reached $64 billion, marking a 22% increase year over year and surpassing the Zacks Consensus Estimate by 8.4% [2][8] Revenue Details - Sales increased by 22% year over year to $64 billion, beating estimates [2] Segmental Analysis - **Pharmaceutical and Specialty Solutions**: Revenues rose 23% to $59.2 billion, driven by growth in branded and specialty pharmaceutical sales [3] - **Pharmaceutical Profit**: Totaled $667 million, up 26% from the previous year, supported by brand and specialty products [4] - **Global Medical Products and Distribution**: Revenues reached $3.2 billion, a 2% increase year over year, with profits rising from $8 million to $46 million [4] - **Other Segment**: Sales grew 38% to $1.6 billion, with profits increasing 60% to $166 million, driven by strong performance across its operating segments [5] Margin Analysis - Gross profit increased 22% year over year to $2.32 billion, with a gross margin of 3.6% [6] - Distribution, selling, general and administrative expenses rose 14% to $1.46 billion [6] - Operating income was $668 million, an 18% increase year over year, with adjusted operating income up 37.1% to $857 million [6] Financial Update - The company ended the quarter with cash and cash equivalents of $4.59 billion, up from $3.87 billion in the previous quarter [9] - Net cash provided by operating activities was $973 million, compared to $1.65 billion used in the same period last year [9] 2026 Outlook - Cardinal Health raised its fiscal 2026 earnings guidance, expecting adjusted EPS between $9.65 and $9.85, up from a prior outlook of $9.30-$9.50 [10] - Projected revenue growth for the Pharmaceutical segment is 11-13%, with segment profit expected to increase 16-19% [10][11] - Medical segment revenues are estimated to grow 2-4%, while the Other segment is expected to see revenue growth of 26-28% [11] Conclusion - The company reported strong first-quarter results, with broad-based profit growth across all segments, particularly in Pharmaceutical and Specialty Solutions [12] - The positive results led to a 10% increase in shares during pre-market trading, with a year-to-date gain of 39.1% compared to the industry’s 4.1% [13]

Company Overview - Henry Schein, Inc. is a leading global provider of healthcare products and services for dental, medical, and veterinary professionals, operating in over 33 countries and delivering more than 300,000 products through its automated distribution network [1] - The company has around 25,000 employees and over one million customers worldwide, with a market capitalization of $7.64 billion [2] Financial Performance - Henry Schein is set to report its third-quarter results for fiscal 2025, with analysts expecting a profit growth of 4.1% year-over-year to $1.27 per diluted share [3] - For the current fiscal year, the company's profit is projected to grow 1.9% annually to $4.83 per diluted share [4] - In its second-quarter earnings for fiscal 2025, the company reported a topline growth of 3.3% year-over-year to $3.24 billion, exceeding Wall Street's expectation of $3.22 billion [6] Stock Performance - Over the past 52 weeks, Henry Schein's stock has declined by 11.7%, and it is down by 7.6% year-to-date, underperforming the broader S&P 500 Index, which gained 14.8% and 14.5% over the same periods [5] - The stock's performance has also lagged behind its sector, as the Health Care Select Sector SPDR Fund has declined by 5.5% over the past 52 weeks but rose 5.3% year-to-date [5] Business Challenges - The company has shown weaknesses in its organic revenue performance, with sales growing only 1.9% year-over-year in Q2 when excluding the impact of acquisitions and foreign currency exchange [7] - The adjusted EPS for Q2 dropped by 10.6% from the previous year to $1.10, missing the expected $1.18, which led to a 7.4% intraday stock decline [6]

Group 1 - Henry Schein, Inc. is at a pivotal juncture with CEO Stanley Bergman's impending retirement and KKR's strategic entry, holding a 14.5% stake and two board seats [2] - The company is projected to achieve $12.7 billion in sales for 2024 and has an $8.5 billion market cap, operating through three main segments: Global Distribution & Value-Added Services, Global Technology, and Global Specialty Products [2] - HSIC has historically underperformed relative to peers due to margin pressures, supply chain disruptions, and rising SG&A and restructuring costs, with revenue growing at a 5% CAGR from 2020 to 2024 [3] Group 2 - KKR's involvement includes a $250 million strategic investment aimed at restructuring, consolidating headquarters, and enhancing e-commerce and SaaS growth, targeting $75–100 million in cost savings by 2025 [4] - The company is expected to transition into a growth-focused enterprise through high-margin SaaS adoption, operational improvements, and strategic asset rationalization, creating an attractive risk/reward setup for investors over the next 18 months [5] - Activist investor Ananym Capital has called for sharper cost control and divestment of non-core assets, which could unlock substantial shareholder value [3][6]

Company Overview - Cardinal Health, Inc. is a healthcare services and products company based in Dublin, Ohio, with a market cap of $35.4 billion, providing customized solutions across various healthcare sectors [1] - The company is classified as a "large-cap stock" due to its market cap exceeding $10 billion, highlighting its size and influence in the medical distribution industry [2] Performance Metrics - Cardinal Health's shares have declined 11.9% from its 52-week high of $168.44, reached on July 1, and have fallen 8.6% over the past three months, underperforming the S&P 500 Index, which rose by 9.5% in the same period [3] - Over the past 52 weeks, Cardinal Health's stock has increased by 31%, outperforming the S&P 500's 17.3% gain, and on a year-to-date basis, shares are up 25.5% compared to the S&P 500's 12.3% return [4] Recent Earnings - On August 12, Cardinal Health's shares dropped 7.2% following a mixed Q4 earnings report, where adjusted EPS was $2.08, a 13% increase from the previous year, surpassing consensus estimates of $2.03, but revenue of $60.2 billion fell slightly short of analyst expectations [5] Competitive Position - Cardinal Health has underperformed compared to its rival, McKesson Corporation, which saw a 33.4% rise over the past 52 weeks, although Cardinal Health has outpaced McKesson's 21.7% return on a year-to-date basis [6]

Core Insights - Cencora, Inc. is a significant player in the pharmaceutical distribution industry, with a market capitalization of $58.7 billion, providing a range of healthcare products and services [1][2] Company Overview - Cencora offers end-to-end pharmaceutical commercialization solutions, over-the-counter healthcare products, home healthcare supplies, and related services to healthcare providers [1] - The company is categorized as a large-cap stock due to its market cap exceeding $10 billion, highlighting its size and influence in the medical distribution sector [2] Financial Performance - In Q3, Cencora reported revenue of $80.7 billion, an increase of 8.7% year-over-year, and adjusted EPS rose by 19.8% to $4 [5] - The company has raised its fiscal 2025 adjusted EPS guidance to a range of $15.85 to $16 [5] Stock Performance - Cencora's stock has seen a year-to-date increase of 34.6% and a 27.3% rise over the past 52 weeks, outperforming the Health Care Select Sector SPDR Fund's marginal gains [4] - Despite a recent drop of 2.2% from its 52-week high of $309.35, the stock has gained 2.5% over the past three months, outperforming the XLV's 1% gain [3][4] Strategic Positioning - The company's strengths include its strategic positioning in the healthcare value chain, a diversified portfolio, and scale-driven bargaining power [2] - Cencora leverages technological capabilities in supply chain management and data analytics to achieve high operational efficiency, with fill rates exceeding 99% [2]

Financial Data and Key Metrics Changes - The company reported a revenue of $3,600,000,000, an increase of 8.3% compared to the previous year [12][9] - Underlying EBITDA reached $95,200,000, up $2,800,000 or about 3% year-on-year [13][12] - Net profit after tax was $31,200,000, with a statutory result of $20,600,000 [9][10] - Free operating cash flow was negative at $11,000,000, significantly impacted by receivables from a group of pharmacies [19][20] Business Line Data and Key Metrics Changes - Revenue from Australia and New Zealand grew to $3,500,000,000, an increase of 8% [21] - Gross margin in Australia and New Zealand was $277,900,000, up 5% [21] - The Asian market saw revenue increase from $84,200,000 to $101,000,000, a growth of 20% [23] Market Data and Key Metrics Changes - Strong growth was noted in Thailand's aesthetics division, contributing to the overall revenue increase in Asia [24] - The imaging business performed solidly despite some market headwinds [24] - Modest growth was observed in the Philippines due to declining contracts [24] Company Strategy and Development Direction - The company aims to continue its growth strategy in Asia following the merger with Paragon Care Group [2][4] - Focus on operational efficiencies and integration of businesses onto a single platform [26][29] - Emphasis on organic growth through investments in sales teams and new business opportunities in dental, robotics, and aesthetics [28][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $12,000,000 in synergies for FY '26, building on the $5,000,000 achieved in FY '25 [26][30] - The competitive landscape in retail pharmacy is evolving, with expectations for continued growth despite challenges [34][35] - Future profitability is expected to improve as synergies are realized and new opportunities are explored [30] Other Important Information - The company completed a refinancing with Scott Pak, increasing local borrowing capacity and reducing interest costs [19][20] - The acquisition of AHP Dental is expected to provide a step into the dental market, with an anticipated EBITDA contribution of around $1,000,000 for FY '26 [46][45] Q&A Session Summary Question: Outlook on revenue and profit for next year - Management indicated that revenue growth would be positive but not necessarily at the same rate as FY '25, suggesting single mid-digit growth rates [33] Question: Competitive landscape in retail pharmacy - Management noted the difficulty in predicting the competitive landscape due to market evolution, particularly following significant mergers [34] Question: Clarification on integration costs in EBITDA - Integration costs were clarified to be excluded from the underlying EBITDA figure [36][37] Question: M&A pipeline and net debt to EBITDA ratio - Management expressed willingness to increase net debt to pursue opportunities, particularly in Asia [38] Question: Details on synergies and cost savings from refinancing - Management confirmed that the $2,000,000 cost saving from refinancing is separate from the $12,000,000 synergy target for FY '26 [43][44] Question: Profitability of recent acquisitions - The AHP Dental acquisition is expected to contribute modestly to EBITDA but offers growth potential in the dental market [46] Question: Focus on growth opportunities in Asia - Management confirmed ongoing efforts to explore acquisitions in Asia that align with current operations [49] Question: Future financing arrangements with Scott Pak - Management indicated a commitment to maintaining the lowest possible cost of funds and flexibility in financing arrangements [57][58]

Financial Data and Key Metrics Changes - The company reported a revenue of $3,600,000,000, reflecting an 8.3% increase compared to the previous year [12][8] - Underlying EBITDA was $95,200,000, up $2,800,000 or about 3% year-on-year, driven by a $25,000,000 increase in gross margin dollars [12][13] - Net profit after tax was $31,200,000, with statutory results showing a net profit of $20,600,000 [8][12] Business Line Data and Key Metrics Changes - Revenue from Australia and New Zealand grew to $3,500,000,000, an increase of 8%, with gross margin rising to $277,900,000, up 5% [21] - The Asian market saw revenue increase from $84,200,000 to $101,000,000, a growth of 20%, with gross margin up by 30% to $46,100,000 [23][24] - Clinical manufacturing signed its first contract manufacturing agreement, indicating growth potential in that segment [22] Market Data and Key Metrics Changes - The Australian pharmacy market experienced solid growth, while hospital pharmacy remained flat [21] - The Asian market, particularly Thailand, showed exceptional growth in aesthetics, contributing significantly to revenue increases [24] - Challenges were noted in Korea due to a doctors' strike, and modest growth was observed in the Philippines due to declining contracts [25] Company Strategy and Development Direction - The company aims to continue its three-two-one strategy, focusing on integrating its businesses and expanding in Asia [27] - There is a strong emphasis on organic growth through investments in sales teams and new business opportunities in dental, robotics, and aesthetics [27][28] - The company is committed to operational efficiencies and simplifying its business structure while exploring merger and acquisition opportunities, particularly in Asia [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving $12,000,000 in synergies for FY '26, building on the $5,000,000 achieved in FY '25 [14][26] - The outlook for revenue and profit growth remains positive, with expectations for improved profitability as synergies are realized [29] - Management highlighted a focus on the competitive landscape in retail pharmacy and the need to adapt to market changes [33] Other Important Information - The company completed a refinancing with Scott Pak, resulting in a $400,000,000 financial covenant-free facility, which is expected to save $2,000,000 in interest annually [18][19] - The company is working towards achieving ISO certifications and GMP accreditation for its facilities [26] Q&A Session Summary Question: Outlook on revenue and profit for next year - Management indicated that revenue growth would be positive but not necessarily at the same rate as FY '25, suggesting single mid-digit growth rates [32] Question: Competitive landscape in retail pharmacy - Management noted that the competitive landscape has evolved, particularly due to recent mergers, and they hope to continue benefiting from trends in the market [33] Question: Clarification on integration costs in EBITDA - Integration costs were clarified to be excluded from the underlying EBITDA, allowing for a clearer view of operational performance [36] Question: M&A pipeline and net debt to EBITDA ratio - Management expressed willingness to increase net debt to pursue opportunities, particularly in Asia, while remaining focused on outcomes [37] Question: Details on recent acquisitions - The AHP Dental acquisition is expected to provide growth opportunities, although it may not contribute significantly to EBITDA initially [46][47] Question: Focus on growth opportunities in Asia - Management confirmed a strong focus on growth opportunities in Asia, with plans to update stakeholders before the AGM [50] Question: Future financing arrangements with Scott Pak - Management confirmed a commitment to maintaining low costs of funds and flexibility in financing arrangements, with a minimum term of two years for the current facility [57]

Core Insights - Henry Schein reported $3.24 billion in revenue for the quarter ended June 2025, a year-over-year increase of 3.3% [1] - The EPS for the same period was $1.10, down from $1.23 a year ago, indicating a decline in earnings [1] - The reported revenue exceeded the Zacks Consensus Estimate of $3.22 billion by 0.6%, while the EPS fell short of the consensus estimate of $1.18 by 6.78% [1] Revenue Breakdown - International Distribution and Value-Added Services - Dental generated $843 million, surpassing the average estimate of $812.72 million, reflecting a 6% year-over-year increase [4] - International Distribution and Value-Added Services - Medical reported $28 million, slightly above the average estimate of $26.36 million, with no year-over-year change [4] - U.S. Distribution and Value-Added Services totaled $1.86 billion, matching analyst estimates but showing an 11.4% decline compared to the previous year [4] - U.S. Distribution and Value-Added Services - Dental Merchandise recorded $602 million, exceeding the average estimate of $595.03 million, but down 29.1% year-over-year [4] - Global Specialty Products net sales were $386 million, slightly above the estimate of $382.44 million [4] - Global Technology net sales were $167 million, compared to the estimate of $161.25 million, reflecting a 22% year-over-year decline [4] - Global Distribution and Value-Added Services net sales reached $2.73 billion, exceeding the estimate of $2.71 billion, but down 6.5% year-over-year [4] - Global Distribution and Value-Added Services - Global Dental reported $1.72 billion, surpassing the estimate of $1.67 billion, with a 10.9% year-over-year decline [4] - Global Distribution and Value-Added Services - Global Medical generated $1.02 billion, slightly below the estimate of $1.03 billion, with a 1.8% year-over-year increase [4] - International Distribution and Value-Added Services totaled $871 million, exceeding the estimate of $839.08 million [4] - Global Distribution and Value-Added Services - Global Dental - Global Equipment reported $439 million, above the estimate of $424.06 million, with a minor 0.2% year-over-year decline [4] Stock Performance - Henry Schein's shares have returned -4.7% over the past month, contrasting with the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Henry Schein, Inc. (HSIC) reported second-quarter 2025 adjusted earnings per share (EPS) of $1.10, a decrease of 10.6% year-over-year, and missed the Zacks Consensus Estimate by 6.8% [1][9] - The company achieved net sales of $3.24 billion, reflecting a year-over-year increase of 3.2%, and exceeded the Zacks Consensus Estimate by 0.6% [2][9] Revenue Breakdown - Global Distribution and Value-Added Services segment sales rose 2.9% year-over-year to $2.73 billion, surpassing the forecast of $2.66 billion [3] - Global Dental Distribution merchandise sales fell 0.4% in constant currencies, while equipment sales increased by 1.6% [4] - Global Medical Distribution sales jumped 6% in constant currencies, driven by increased patient traffic and growth from acquisitions [4] - Global Specialty Products sales totaled $386 million, up 4.2% year-over-year, reflecting growth in implant and biomaterial sales [6] - Global Technology segment sales reached $167 million, a 7.4% increase, led by strong growth in practice management systems [7] Margin Performance - Gross profit for the quarter was $1.02 billion, a 0.2% decrease year-over-year, with gross margin contracting by 110 basis points to 31.4% due to a 5% rise in the cost of sales [8][9] - SG&A expenses declined by 0.4% to $778 million, while adjusted operating profit increased by 0.4% year-over-year to $238 million [10] Liquidity and Share Repurchase - At the end of Q2 2025, the company had cash and cash equivalents of $145 million, up from $127 million at the end of Q1 [11] - Cumulative net cash provided by operating activities was $157 million, down from $493 million year-over-year, with nearly 3.7 million shares repurchased at an average price of $70.88 per share [12] Guidance - The company maintained its adjusted EPS forecast for 2025 in the range of $4.80-$4.94, indicating 1-4% growth from 2024 [13] - Projected revenue growth for 2025 remains unchanged at nearly 2-4% compared to the previous year [13] Strategic Outlook - The company is advancing its BOLD+1 Strategic Plan for 2025 to 2027, focusing on operational efficiency, enhancing customer experience, and growing its digital footprint [15]

Financial Performance - Q2 2025 - Total sales increased by 3.3% to $3.24 billion[18, 54], with constant currency growth of 2.7%[15, 19, 22] - Non-GAAP diluted EPS was $1.10, a decrease of 10.6% compared to $1.23 in Q2 2024[15, 18, 54] - Adjusted EBITDA was $256 million, a decrease of 4.8% compared to $268 million in Q2 2024[15, 18, 57] - Global Distribution and Value-Added Services Group sales grew by 2.4% in constant currency[15, 22] - Global Specialty Products Group sales grew by 3.3%[15, 22] - Global Technology Group sales grew by 6.6%[15, 22] Segment Performance - U S dental merchandise sales decreased 1.2%[22] - International dental merchandise constant currency sales grew 0.5%[22] - U S Medical sales grew 6.3% including acquisitions[22] Guidance and Strategy - The company maintains 2025 non-GAAP diluted EPS guidance of $4.80 to $4.94[12, 46, 48] - 2025 Adjusted EBITDA is expected to grow in the mid-single digits versus 2024 Adjusted EBITDA of $1.1 billion[46] - Total sales growth for 2025 is projected to be between 2% and 4%[12, 48]